Treatment of cognitive impairment in multiple sclerosis: Is the use of acetylcholinesterase inhibitors a viable option?

CNS Drugs

Volumn 22, Issue 2, 2008, Pages 87-97

  Christodoulou, Christopher ^a   MacAllister, William S ^b   McLinskey, Nancy A ^a   Krupp, Lauren B ^a  

^a STONY BROOK UNIVERSITY   (United States)

^b NEW YORK UNIVERSITY   (United States)

Author keywords

Antidementias, therapeutic use; Cholinesterase inhibitors, therapeutic use; Cognitive function; Donepezil, therapeutic use; Multiple sclerosis; Physostigmine, therapeutic use

Indexed keywords

3,4 DIAMINOPYRIDINE; 4 AMINOPYRIDINE; AMANTADINE; CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; GLATIRAMER; PEMOLINE; PHYSOSTIGMINE; POTASSIUM CHANNEL BLOCKING AGENT; RIVASTIGMINE;

CHRONIC DISEASE; CLINICAL TRIAL; COGNITION; COGNITIVE DEFECT; DIARRHEA; DISABILITY; DRUG TOLERABILITY; FAMILY; HEART DISEASE; HUMAN; LEARNING; LONG TERM CARE; MULTIPLE SCLEROSIS; NEUROPSYCHOLOGICAL TEST; NOTE; PRIORITY JOURNAL; SOCIAL ASPECT; SYMPTOMATOLOGY; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

CHOLINESTERASE INHIBITORS; COGNITION DISORDERS; HUMANS; MULTIPLE SCLEROSIS;

EID: 38149115344     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-200822020-00001     Document Type: Note

References (99)

1. Kurtzke JF, Page WF, Murphy FM, et al. Epidemiology of multiple sclerosis in United States veterans: 4. Age at onset. Neuroepidemiology 1992; 11: 226-35
2. Peyser JM, Edwards KR, Poser CM, et al. Cognitive function in patients with multiple sclerosis. Arch Neurol 1980; 37 (9): 577-9
3. Rao SM, Leo GJ, Bernardin L, et al. Cognitive dysfunction in multiple sclerosis: I. Frequency, patterns, and prediction. Neurology 1991; 41 (5): 685-91
4. Thornton AE, Raz N. Memory impairment in multiple sclerosis: a quantitative review. Neuropsychology 1997; 11 (3): 357-66
5. Deluca J, Gaudino EA, Diamond BJ, et al. Acquisition and storage deficits in multiple sclerosis. J Clin Exp Neuropsychol 1998; 20 (3): 376-90
6. Beatty WW, Wilbanks SL, Blanco CR, et al. Memory disturbance in multiple sclerosis: reconsideration of patterns of performance on the selective reminding test. J Clin Exp Neuropsychol 1996; 18 (1): 56-62
7. Ruchkin DS, Grafman J, Krauss GL, et al. Event-related brain potential evidence for a verbal working-memory deficit in multiple-sclerosis. Brain 1994; 117: 289-305
8. Diamond BJ, Deluca J, Kim HJ, et al. The question of disproportionate impairments in visual and auditory information processing in multiple sclerosis. J Clin Exp Neuropsychol 1997; 19 (1): 34-42
9. D'Esposito M, Onishi K, Thompson H, et al. Working memory impairments in multiple sclerosis: evidence from a dual-task paradigm. Neuropsychology 1996; 10 (1): 51-6
10. Beatty WW, Goodkin DE, Beatty PA, et al. Frontal-lobe dysfunction and memory impairment in patients with chronic progressive multiple-sclerosis. Brain Cogn 1989; 11 (1): 73-86
11. Arnett PA, Rao SM, Grafman J, et al. Executive functions in multiple sclerosis: an analysis of temporal ordering, semantic encoding, and planning abilities. Neuropsychology 1997; 11 (4): 535-44
12. Foong J, Rozewicz L, Quaghebeur G, et al. Executive function in multiple sclerosis: the role of frontal lobe pathology. Brain 1997; 120 (Pt 1): 15-26
13. van den Burg W, van Zomeren AH, Minderhoud JM, et al. Cognitive impairment in patients with multiple sclerosis and mild physical disability. Arch Neurol 1987; 44: 494-501
14. Minden SL, Moes EJ, Orav J, et al. Memory impairment in multiple-sclerosis. J Clin Exp Neuropsychol 1990; 12 (4): 566-86
15. Huijbregts SCJ, Kalkers NF, de Sonneville LMJ, et al. Differences in cognitive impairment of relapsing remitting, secondary, and primary progressive MS. Neurology 2004; 63 (2): 335-9
16. Denney DR, Sworowski LA, Lynch SG. Cognitive impairment in three subtypes of multiple sclerosis. Arch Clin Neuropsychol 2005; 20 (8): 967-81
17. Huijbregts SCJ, Kalkers NF, de Sonneville LMJ, et al. Cognitive impairment and decline in different MS subtypes. J Neurol Sci 2006; 245 (1-2): 187-94
18. Wachowius U, Talley M, Silver N, et al. Cognitive impairment in primary and secondary progressive multiple sclerosis. J Clin Exp Neuropsychol 2005; 27 (1): 65-77
19. Achiron A, Barak Y. Cognitive impairment in probable multiple sclerosis. J Neurol Neurosurg Psychiatry 2003; 74 (4): 443-6
20. Amato MP, Zipoli V, Goretti B, et al. Benign multiple sclerosis: cognitive, psychological and social aspects in a clinical cohort. J Neurol 2006; 253 (8): 1054-9
21. Amato MP, Ponziani G, Pracucci G, et al. Cognitive impairment in early-onset MS: a reappraisal after a 10-year follow-up [abstract]. Neurology 1999; 52 (6): A499
22. Kujala P, Portin R, Ruutiainen J. The progress of cognitive decline in multiple sclerosis: a controlled 3-year follow-up. Brain 1997; 120 (Pt 2): 289-97
23. Rao SM, Leo GJ, Ellington L, et al. Cognitive dysfunction in multiple sclerosis: II. Impact on employment and social functioning. Neurology 1991; 41 (5): 692-6
24. Beatty WW. Cognitive and emotional disturbances in multiple sclerosis. Neurol Clin 1993; 11 (1): 189-204
25. Beatty WW, Blanco CR, Wilbanks SL, et al. Demographic, clinical, and cognitive characteristics of multiple sclerosis patients who continue to work. J Neurol Rehabil 1995; 9: 167-73
26. Wild KV, Lezak M, Whitman RH, et al. Psychosocial impact of cognitive impairment in the multiple sclerosis patient [abstract]. J Clin Exp Neuropsychol 1991; 13: 74
27. Schultheis MT, Garay E, Millis SR, et al. Motor vehicle crashes and violations among drivers with multiple sclerosis. Arch Phys Med Rehabil 2002; 83 (8): 1175-8
28. Schultheis MT, Garay E, Deluca J. The influence of cognitive impairment on driving performance in multiple sclerosis. Neurology 2001; 56 (8): 1089-94
29. Shawaryn MA, Schultheis MT, Garay E, et al. Assessing functional status: exploring the relationship between the multiple sclerosis functional composite and driving. Arch Phys Med Rehabil 2002; 83 (8): 1123-9
30. Fischer JS. Assessment of neuropsychological function. In: Rudick RA, Goodkin DE, editors. Multiple sclerosis therapeutics. London: Martin Dunitz, 1999: 31-47
31. Cummings JL. Use of cholinesterase inhibitors in clinical practice: evidence-based recommendations. Am J Geriatr Psychiatry 2003; 11 (2): 131-45
32. Rogers SL, Farlow MR, Doody RS, et al. A 24-week, double-blind, placebo-controlled trial of donezepil in patients with Alzheimer's disease. Neurology 1998; 50: 136-45
33. Burns A, Rossor M, Hecker J, et al. The effects of donepezil in Alzheimer's disease: results from a multinational trial. Dement Geriatr Cogn Disord 1999; 10 (3): 237-44
34. Evans JG, Wilcock G, Birks J. Evidence-based pharmacotherapy of Alzheimer's disease. Int J Neuropsychopharmacol 2004; 7 (3): 351-69
35. Birks JS, Harvey R. Donepezil for dementia due to Alzheimer's disease. Cochrane Database Syst Rev 2003; (3): CD001190
36. Winblad B, Engedal K, Soininen H, et al. A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology 2001; 57 (3): 489-95
37. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry 1984; 141 (11): 1356-64
38. Schneider LS, Olin JT, Doody RS, et al. Validity and reliability of the Alzheimer's Disease Cooperative Study-clinical global impression of change. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord 1997; 11 Suppl. 2: S22-32
39. Cohen J. Statistical power analysis for the behavioral sciences. 2nd ed. Hillsdale (NJ): Lawrence Erlbaum Associates, 1988
40. NMSS Cognition and MS Task Force. Assessment and management of cognitive impairment in multiple sclerosis. Expert opinion paper from the Medical Advisory Board of the National Multiple Sclerosis Society, 2006 [online]. Available from URL: http://www.nationalmssociety.org/site/PageServer?pagename= HOM_PRO_expert_opinion_papers [Accessed 2007 Dec 19]
41. Chiaravalloti ND, Deluca J. Self-generation as a means of maximizing learning in multiple sclerosis: an application of the generation effect. Arch Phys Med Rehabil 2002; 83 (8): 1070-9
42. Chiaravalloti ND, Deluca J, Moore NB, et al. Treating learning impairments improves memory performance in multiple sclerosis: a randomized clinical trial. Multiple Sclerosis 2005; 11 (1): 58-68
43. Fischer JS, Priore RL, Jacobs LD, et al. Neuropsychological effects of interferon beta-1a in relapsing multiple sclerosis. Multiple Sclerosis Collaborative Research Group. Ann Neurol 2000; 48 (6): 885-92
44. Pliskin NH, Hamer DP, Goldstein DS, et al. Improved delayed visual reproduction test performance in multiple sclerosis patients receiving interferon beta-1b. Neurology 1996; 47 (6): 1463-8
45. Weinstein A, Schwid SI, Schiffer RB, et al. Neuropsychologic status in multiple sclerosis after treatment with glatiramer. Arch Neurol 1999; 56 (3): 319-24
46. Boringa JB, Lazeron RH, Reuling IE, et al. The brief repeatable battery of neuropsychological tests: normative values allow application in multiple sclerosis clinical practice. Mult Scler 2001; 7 (4): 263-7
47. Greene YM, Tariot PN, Wishart H, et al. A 12-week, open trial of donepezil hydrochloride in patients with multiple sclerosis and associated cognitive impairments. J Clin Psychopharmacol 2000; 20 (3): 350-6
48. Jonsson A, Korfitzen EM, Heltberg A, et al. Effects of neuropsychological treatment in patients with multiple sclerosis. Acta Neurol Scand 1993; 88 (6): 394-400
49. Leo GJ, Rao SM. Effects of intravenous physostigmine and lecithin on memory in multiple sclerosis: report of a pilot study. J Neurol Rehabil 1988; 2: 123-9
50. Plohmann AM, Kappos L, Ammann W, et al. Computer assisted retraining of attentional impairments in patients with multiple sclerosis. J Neurol Neurosurg Psychiatry 1998; 64 (4): 455-62
51. Krupp LB, Christodoulou C, Melville P, et al. Interventions to improve memory in MS. The aricept in MS study (AIMS): 24 week data. Neurology 2003; 60 Suppl. 1: A477
52. Bever Jr CT, Anderson PA, Leslie J, et al. Treatment with oral 3,4 diaminopyridine improves leg strength in multiple sclerosis patients: results of a randomized, double-blind, placebo-controlled, crossover trial. Neurology 1996; 47 (6): 1457-62
53. Geisler MW, Sliwinski M, Coyle PK, et al. The effects of amantadine and pemoline on cognitive functioning in multiple sclerosis. Arch Neurol 1996; 53 (2): 185-8
54. Oliveri RL, Valentino P, Russo C, et al. Randomized trial comparing two different high doses of methylprednisolone in MS: a clinical and MRI study. Neurology 1998; 50 (6): 1833-6
55. Rodgers D, Khoo K, MacEachen M, et al. Cognitive therapy for multiple sclerosis: a preliminary study. Altern Ther Health Med 1996; 2 (5): 70-4
56. Smits RC, Emmen HH, Bertelsmann FW, et al. The effects of 4-aminopyridine on cognitive function in patients with multiple sclerosis: a pilot study. Neurology 1994; 44 (9): 1701-5
57. Cohen RA, Fisher M. Amantadine treatment of fatigue associated with multiple-sclerosis. Arch Neurol 1989; 46 (6): 676-80
58. Rossini PM, Pasqualetti P, Pozzilli C, et al. Fatigue in progressive multiple sclerosis: results of a randomized, double-blind, placebo-controlled, crossover trial of oral 4-aminopyridine. Mult Scler 2001; 7 (6): 354-8
59. Unverzagt FW, Rao SM, Antuono PG. Oral physostigmine in the treatment of memory loss in multiple sclerosis (MS) [abstract]. J Clin Exp Neuropsychol 1991; 13 (1): 74
60. Krupp LB, Elkins LE, Scheffer S, et al. Donepezil for the treatment of memory impairments in multiple sclerosis [abstract]. Neurology 1999; 52 Suppl. 2: A137
61. Rorie KD, Stump DA, Jeffery DR. Effects of donepezil on cognitive function in patients with multiple sclerosis [abstract]. Neurology 2001; 56 Suppl. 3: A99
62. Krupp LB, Christodoulou C, Melville P, et al. Donepezil improved memory in multiple sclerosis in a randomized clinical trial. Neurology 2004; 63: 1579-85
63. Decoo D. Effects of donepezil in multiple sclerosis: a single-centre trial [abstract]. Multiple Sclerosis 2004; 10 (7032): S150
64. Bosça L, Andreu M, Bueno A, et al. Donepezil and cognitive impairment in multiple sclerosis: a double-blind pilot study [abstract]. Multiple Sclerosis 2004; 10 (7032): S150
65. Buschke H, Fuld PA. Evaluating storage, retention, and retrieval in disordered memory and learning. Neurology 1974; 24 (11): 1019-25
66. Coelho F, Birks J. Physostigmine for Alzheimer's disease. Cochrane Database Syst Rev 2001; (2): CD001499
67. Rao SM, Cognitive Function Study Group of the National Multiple Sclerosis Society. A manual for the brief, repeatable battery of neuropsychological tests in multiple sclerosis. Milwaukee (WI): Section of Neuropsychology, Medical College of Wisconsin, 1990
68. Harris G. Study of Alzheimer's drug revives questions on risk. New York Times, 2006 Mar 17
69. Levin HS, Peters BH, Kalisky Z, et al. Effects of oral physostigmine and lecithin on memory and attention in closed head-injured patients. Cent Nerv Syst Trauma 1986; 3 (4): 333-42
70. Taverni JP, Seliger G, Lichtman SW. Donepezil medicated memory improvement in traumatic brain injury during post acute rehabilitation. Brain Inj 1998; 12 (1): 77-80
71. Whitlock Jr JA. Brain injury, cognitive impairment, and donepezil. J Head Trauma Rehabil 1999; 14 (4): 424-7
72. Maidment I, Fox C, Boustani M. Cholinesterase inhibitors for Parkinson's disease dementia. Cochrane Database Syst Rev 2006; (1): CD004747
73. Aarsland D, Laake K, Larsen JP, et al. Donepezil for cognitive impairment in Parkinson's disease: a randomised controlled study. J Neurol Neurosurg Psychiatry 2002; 72 (6): 708-12
74. Emre M, Aarsland D, Albanese A, et al. Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med 2004; 351 (24): 2509-18
75. Fernandez HH, Friedman JH, Grace J, et al. Donepezil for Huntington's disease. Mov Disord 2000; 15 (1): 173-6
76. Kishnani PS, Sullivan JA, Walter BK, et al. Cholinergic therapy for Down's syndrome. Lancet 1999; 353 (9158): 1064-5
77. Erkinjuntti T, Kurz A, Gauthier S, et al. Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial. Lancet 2002; 359 (9314): 1283-90
78. Roman GC, Wilkinson DG, Doody RS, et al. Donepezil in vascular dementia: combined analysis of two large-scale clinical trials. Dement Geriatr Cogn Disord 2005; 20 (6): 338-44
79. Furey ML, Pietrini P, Haxby JV, et al. Cholinergic stimulation alters performance and task-specific regional cerebral blood flow during working memory. Proc Natl Acad Sci U S A 1997; 94 (12): 6512-6
80. Furey ML, Pietrini P, Alexander GE, et al. Cholinergic enhancement improves performance on working memory by modulating the functional activity in distinct brain regions: a positron emission tomography regional cerebral blood flow study in healthy humans. Brain Res Bull 2000; 51 (3): 213-8
81. Furey ML, Pietrini P, Haxby JV. Cholinergic enhancement and increased selectivity of perceptual processing during working memory. Science 2000; 290 (5500): 2315-9
82. Hutchison CW, Nathan PJ, Mrazek L, et al. Cholinergic modulation of speed of early information processing: the effect of donepezil on inspection time. Psychopharmacology (Berl) 2001; 155 (4): 440-2
83. Yesavage JA, Mumenthaler MS, Taylor JL, et al. Donepezil and flight simulator performance: effects on retention of complex skills. Neurology 2002; 59 (1): 123-5
84. Mumenthaler MS, Yesavage JA, Taylor JL, et al. Psychoactive drugs and pilot performance: a comparison of nicotine, donepezil, and alcohol effects. Neuropsychopharmacology 2003; 28 (7): 1366-73
85. Rogers SL, Doody RS, Mohs RC, et al. Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group. Arch Intern Med 1998; 158 (9): 1021-31
86. Rogers SL, Friedhoff LT. The efficacy and safety of donepezil in patients with Alzheimer's disease: results of a US multicentre, randomized, double-blind, placebo-controlled trial. The Donepezil Study Group. Dementia 1996; 7 (6): 293-303
87. Ruberg M, Villageois A, Bonnet AM, et al. Acetylcholinesterase and butyrylcholinesterase activity in the cerebrospinal fluid of patients with neurodegenerative diseases involving cholinergic systems. J Neurol Neurosurg Psychiatry 1987; 50 (5): 538-43
88. D'Intino G, Paradisi M, Fernandez M, et al. Cognitive deficit associated with cholinergic and nerve growth factor down-regulation in experimental allergic encephalomyelitis in rats. Proc Natl Acad Sci U S A 2005; 102 (8): 3070-5
89. Trapp BD, Peterson J, Ransohoff RM, et al. Axonal transection in the lesions of multiple sclerosis. N Engl J Med 1998; 338 (5): 278-85
90. Chamelian L, Bocti C, Gao FQ, et al. Detecting cognitive dysfunction in multiple sclerosis with a magnetic resonance imaging rating scale: a pilot study. CNS Spectr 2005; 10 (5): 394-401
91. Blin J, Ray CA, Piercey MF, et al. Comparison of cholinergic drug effects on regional brain glucose consumption in rats and humans by means of autoradiography and position emission tomography. Brain Res 1994; 635 (1-2): 196-202
92. Hakansson L. Mechanism of action of cholinesterase inhibitors in Alzheimer's disease. Acta Neurol Scand Suppl 1993; 149: 7-9
93. Nordberg A, Lilja A, Lundqvist H, et al. Tacrine restores cholinergic nicotinic receptors and glucose metabolism in Alzheimer patients as visualized by positron emission tomography. Neurobiol Aging 1992; 13 (6): 747-58
94. Robbins TW, Mehta MA, Sahakian BJ. Neuroscience: boosting working memory. Science 2000; 290 (5500): 2275-6
95. Parry AMM, Scott RB, Palace J, et al. Potentially adaptive functional changes in cognitive processing for patients with multiple sclerosis and their acute modulation by rivastigmine. Brain 2003; 126: 2750-60
96. Saykin AJ, Wishart HA, Rabin LA, et al. Cholinergic enhancement of frontal lobe activity in mild cognitive impairment. Brain 2004; 127 (Pt 7): 1574-83
97. Tsao JW, Heilman KM. Transient memory impairment and hallucinations associated with tolterodine use. N Engl J Med 2003; 349 (23): 2274-5
98. Turner DC, Robbins TW, Clark L, et al. Cognitive enhancing effects of modafinil in healthy volunteers. Psychopharmacology 2003; 165 (3): 260-9
99. Porrino LJ, Daunais JB, Rogers GA, et al. Facilitation of task performance and removal of the effects of sleep deprivation by an ampakine (CX717) in nonhuman primates. Plos Biology 2005; 3 (9): 1639-52